Celldex Therapeutics (CLDX) Shares Outstanding (2010 - 2026)

Celldex Therapeutics' Shares Outstanding (Entity) history runs 14 years deep, the most recent figure standing at $48449.0 for Q4 2023.

• On a quarterly basis, Shares Outstanding (Entity) rose 3.33% year-over-year to $48449.0 in Q4 2023; TTM through Dec 2023 was $48449.0, a 3.33% increase from a year earlier, with the FY2023 full-year figure at $48449.0, up 3.33% from the prior year.
• Shares Outstanding (Entity) climbed to $48449.0 in Q4 2023 per CLDX's latest filing, from $47261.0 in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $47.1 million in Q3 2022 and bottomed at $29640.0 in Q4 2020.
• The 5-year median for Shares Outstanding (Entity) is $16.4 million (2019), against an average of $20.3 million.
• Across the five-year window, Shares Outstanding (Entity) soared 148.75% in 2020 and slumped 99.9% in 2023, its largest moves.
• Year by year, Shares Outstanding (Entity) stood at $17.0 million in 2019, then sank by 99.83% to $29640.0 in 2020, then surged by 44.64% to $42870.0 in 2021, then rose by 9.37% to $46888.0 in 2022, then increased by 3.33% to $48449.0 in 2023.
• Per Business Quant, the three latest CLDX Shares Outstanding (Entity) figures stand at $48449.0 (Q4 2023), $47261.0 (Q3 2023), and $47253.0 (Q2 2023).